

Press Release

Vetbiolix strengthens its pipeline with the SOLUDOTS-Paclitaxel product licensed from CARLINA Technologies for the veterinary oncology market

Lille, 08th July 2020 – Vetbiolix, a French-based veterinary biotech company announced today having entered into a worldwide, exclusive license and research agreement with CARLINA Technologies, a French-based contract service-based biotechnology company specialized in the development of nanomedicines to enter clinical development phase of SOLUDOTS-Paclitaxel for the treatment of cancer in companion animals. This agreement extends the veterinary oncology portfolio of Vetbiolix which currently includes a lateral flow assay development program to monitor cancer in companion animals, as well as others drug development programs in complex and age-related diseases affecting pets. The collaboration with CARLINA Technologies, a renowned expert in the development controlled-release formulations of medicines for human and animal health, is projected to advance the program into veterinary clinical development phases of development within 6 months.

SOLUDOTS-Paclitaxel is an improved version of the anticancer product Taxol™, that showed improved antitumor activity over Taxol™ in human lung and ovary cancer models in mice. Preclinical safety evaluation antitumor in mice and rats have showed that SOLUDOTS-PTX was 10-fold less toxic than Taxol™. SOLUDOTS-PTX is well tolerated in dogs at equivalent Taxol™ clinical dose used un humans without premedication.

Rapidly growing adoption of dogs and cats, because of improving economic status of people coupled with increasing pet healthcare expenditure, will drive the pet cancer therapeutics market in the coming years. Pet cancer therapeutics market accounted for USD 145 million in 2016 and is anticipated to reach USD 320 million in 2024, growing at a CAGR of 10.4% over the forecast timeframe. Rising incidences of cancer in dogs and cats, the growing awareness about cancer among their owners, and increasing specialization of veterinarians in oncology will drive chemotherapy drugs market which currently remains the gold standard treatment with surgery and radiotherapy. Pet chemotherapy drugs market accounted for USD 100.2 million in 2016 and is anticipated to reach USD 190.7 million in 2024, growing at a CAGR of 9.1% over the forecast timeframe.

Matthieu Roquette, President at Vetbiolix commented: « We approached CARLINA Technologies because of their experience in drug delivery system developments, making an efficient well-known anti-cancer drug, Taxol™, adapted to cancer management of pets by veterinarian specialized in oncology. The pet cancer therapeutic market is a priority for Vetbiolix with two major programs ongoing along with SOLUDOTS-Paclitaxel from now on: Our team built one the most promising network in this domain regrouping, in Europe and US, a large network of veterinary oncologists key opinion leaders involved in clinical research, the two best vet-CRO specialized in Veterinary Oncology, and experienced regulatory experts. »

Olivier Meyer, President & CEO of CARLINA Technologies, commented: « We are delighted to start this partnership with Vetbiolix on the development of innovative oncology treatments for companion animals. This collaboration will provide evidence that our lipid nanocapsules technology called SOLUDOTS represents an ideal drug delivery system to efficiently and safely deliver poorly water-soluble antineoplastic agents such as taxanes to treat pets having cancer. »

About Vetbiolix – <https://www.vetbiolix.com>

Vetbiolix develops innovative products for treatment and prevention of diseases affecting pets. As pharmaceutical and biotech companies research novel molecules and compounds for human medicine, tests in different species often reveal exciting possibilities for pets. Vetbiolix has developed a unique approach focused on turning this potential into innovative prescription medicines and care products for pets. To date, veterinarians have still few therapeutics and real preventive care products at their disposal that have been specifically developed and approved for pets. Along with a virtual VetBiotech organization, Vetbiolix exclusively focuses on clinical developments of prescription medicines, diagnostics, nutraceuticals and care products for pets, thanks to its qualified external R&D partners in Europe & the US. Vetbiolix is supported by the Eurasanté Bio-Incubator, the northern France health cluster ranked among the top 20 best European incubators fostering pharm/biotech start-up development (Labiotech.eu 2019).

Contact: matthieu.roquette@vetbiolix.com

About CARLINA Technologies – <https://www.carlinatech.com>

CARLINA Technologies is a nanomedicine development company providing both formulation development services and drug delivery system out-licensing opportunities to the biopharmaceutical industries. Using its proprietary controlled-delivery technologies applicable to a wide range of active pharmaceutical ingredients including small molecules, proteins, peptides, and nucleic acid-based therapeutics, CARLINA Technologies develops innovative nanomedicines for both human and animal health.

Contact: olivier.meyer@carlinatech.com